A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

This study tests whether adding an immunotherapy drug called adebrelimab to chemotherapy (XELOX: capecitabine and oxaliplatin) given before and after surgery improves outcomes for patients with resectable (surgically removable) locally advanced stomach or gastroesophageal junction (GEJ) cancer. **You may be eligible if...** - You are 18–75 years old with confirmed stomach or GEJ adenocarcinoma - Your cancer is Stage II–III and considered surgically removable - You have not received any prior cancer treatment - You have at least one measurable tumor on imaging - You are in good general health (ECOG 0–1) - Your liver, kidneys, and blood function are adequate **You may NOT be eligible if...** - Your cancer cannot be surgically removed - You have already received treatment for this cancer - You have active hepatitis B - You are pregnant or breastfeeding - You have serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.